A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer
Overview
- Phase
- Not Applicable
- Intervention
- immunity therapy
- Conditions
- Non Small Cell Lung Cancer
- Sponsor
- Yongchang Zhang
- Enrollment
- 186
- Locations
- 2
- Primary Endpoint
- PFS
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.
Investigators
Yongchang Zhang
Director, Head of Medical Oncology, Principal Investigator, Clinical Professor
Hunan Province Tumor Hospital
Eligibility Criteria
Inclusion Criteria
- •1.Diagnosed as advanced non-small cell lung cancer
- •2.Confirmed as KARS, ALK, ERBB2, MET, RET, BRAF mutation
Exclusion Criteria
- •The patient is diagnosed with small cell lung cancer
Arms & Interventions
KRAS mutation
patients carry with KRAS mutation
Intervention: immunity therapy
ALK fusion
patients carry with ALK fusion
Intervention: immunity therapy
ERBB2 mutation
patients carry with ERBB2 mutation
Intervention: immunity therapy
MET skipping/amplication
patients carry with MET skipping/amplication
Intervention: immunity therapy
RET fusion
patients carry with RET fusion
Intervention: immunity therapy
BRAF mutation
patients carry with BRAF mutation
Intervention: immunity therapy
Outcomes
Primary Outcomes
PFS
Time Frame: January 2021- January 2021 (1 year)
Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)